BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
May 30, 2001
View Archived Issues
Licensing opportunity from NIH: human nuclear receptor corepressor gene
Read More
Antibodies that selectively detect human nestin protein available from NIH
Read More
Licensing opportunity from NIH: bispecific fusion proteins for HIV infection
Read More
Yamanouchi identifies ethenesulfonamide ETA antagonist with good selectivity and oral activity
Read More
Synthetic IFN-gamma-derived peptide delays rejection of vascularized skin allografts
Read More
New combination treatment for malaria launched in Europe
Read More
Novartis launches Foradil Aerolizer in the U.S.
Read More
European group develops new molecular modeling tools for H3 antagonists
Read More
Locally active estrogens useful for menopausal vaginal dyspareunia
Read More
Telik begins phase II trial of TLK-286 for treatment of ovarian cancer
Read More
Oxxon Pharmaccines begins melanoma pharmaccine trials
Read More
ISAtx-247 highlighted at Transplant 2001 as having potential advantages over ciclosporin
Read More
Company Profile: Galileo Laboratories
Read More
Prescient NeuroPharma establishes collaboration with CNRS
Read More
Recombinant AAT closer to obtaining orphan drug designation in E.U.
Read More
Favorable phase I data presented for Bay-43-9006 at ASCO
Read More
Solid dosage form of antibody for UC to be developed by KS Biomedix and MedPharm
Read More
Combination therapy containing IMC-C225 beneficial in cancer patients with limited options
Read More
Takeda's Ixense approved in Europe for ED
Read More
Company Profile: Consensus
Read More
MCH antagonists and their utility described by Takeda
Read More
Potent new PDE5 inhibitors designed by Pfizer group
Read More
Improvement in glucose tolerance and insulin secretion produced by Shionogi compounds
Read More
Quinazolinones and related compounds and use as local anesthetics
Read More
New CCR5 antagonists designed at Takeda as agents for HIV
Read More
New antifungal/antibacterial enediyne compounds
Read More
Welfide describes new research in the area of cytokine modulation
Read More
Inhibitors of 5-HT reuptake and potential therapeutic applications presented by ADIR
Read More